SOLACEA-H in Heparin-sparing Haemodialysis

NARecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Dialysis Membrane Reaction
Interventions
DEVICE

SOLACEA-H/HYDROLINK-NVU

Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.

DEVICE

HYDROLINK-NVU/SOLACEA-H

Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.

Trial Locations (1)

59800

RECRUITING

Hôpital Privé La Louvière, Lille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Euraxi Pharma

INDUSTRY

lead

GCS Ramsay Santé pour l'Enseignement et la Recherche

OTHER

NCT06281028 - SOLACEA-H in Heparin-sparing Haemodialysis | Biotech Hunter | Biotech Hunter